``We don't know why, when they get diabetes, they have a moresevere form of the disease _ whether it's a biological difference oris it that they are not getting as good medical care.
``The problem with Type II diabetics is not that they don't makeenough insulin; they don't respond to the insulin,'' DeFronzo said.``What we'd like to do is make them more responsive and this drugwill do that.''
